Comparison of Efficacies of Sofosbuvir/Daclatasvir with Sofosbuvir/Ribavirin for Hepatitis C Virus Genotype 3 Treatment in a Tertiary Care Center in Karachi
Keywords:
Cirrhosis, Ribavirin, Daclatasvir, SVR, SofosbuvirAbstract
Hepatitis C virus infection (HepCV) is a significant health issue globally, which leads to several liver diseases, including cirrhosis and hepatocellular carcinomas. There is a class of drugs knowns as DAA, which has changed the spectrum of chronic HepCV treatment modality. HepCV genotype 3 is more prevalent in Pakistan and more aggressive, leading to HCC. We studied the drug response in SVR or sustained virological response in HepCV-infected patients on daclatasvir and sofosbuvir compared to sofosbuvir ribavirin in the local population. Over two years, this retrospective study was performed at the Department of Gastroenterology, Ziauddin Hospital, North campus. It was a prospective cohort study. All patients harboring HepCV genotype 3a infection were classified into A and B groups. Group A was treated with a combination of sofosbuvir and daclatasvir, while group B was treated with sofosbuvir and ribavirin. Both groups included cirrhotic and noncirrhotic patients and measured the outcome as SVR3 after 12 weeks of the end of therapy. Three hundred patients were included in the study, out of which 182 (60.06%) were male while 118 (39.33%) were females. We observed that non-cirrhotic patients achieved SVR3 of 100% when they received daclatasvir/sofosbuvir therapy compared to 93.6% in patients who received Sofosbuvir and ribavirin. On the other hand, cirrhotic patients achieved SVR3 of 92% when receiving Sofosbuvir and Daclatasvir compared to 72% in those who received Sofosbuvir and ribavirin. Sofosbuvir, along with daclatasvir, was more effective than sofosbuvir and ribavirin alone in genotype-3 infected hepatitis C patients.
Downloads
References
Baumert, T. F., Berg, T., Lim, J. K., & Nelson, D. R. (2019). Status of direct-acting
antiviral therapy for hepatitis C virus infection and remainingchallenges. Gastroenterology, 156(2), 431-445.
Lim, A. G., Qureshi, H., Mahmood, H., Hamid, S., Davies, C. F., Trickey, A., et al. (2018).
Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and
prevention for achieving elimination. Int. J. Epidemiol. 47 (2), 550–560.
Organization, W. H. (2017). Regional action plan for the implementation of the global
health sector strategy on viral hepatitis 2017–2021 (World Health Organization. Regional
Office for the Eastern Mediterranean). Available
at: https://apps.who.int/iris/handle/10665/258729.
Khan, S., Ali, I., Badshah, M., Khan, Q. M., Haider, Z. N., Ali, S., et al. (2019). Molecular
Epidemiology of Hepatitis C Virus Genotypes Among Chronically Infected Patients in
Pakistan. Jundishapur J. Microbiol. 12 (3), 1–7.
Al Kanaani, Z., Mahmud, S., Kouyoumjian, S. P., Abu-Raddad, L. J. (2018). The
epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R.
Soc. Open Sci. 5 (4), 180257.
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar,
R., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus
ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (9286),
–965.
Ali, S., Ahmad, B., Ali, I., Mahmood, N., Anwar, N., Saeedi, I., et al. (2016). Virological
response to conventional interferon therapy combined with ribavirin against various HCV
genotypes in Khyber Pakhtunkhwa, Pakistan. Asian Pacific J. Cancer Prev. 17 (5), 2407–
Spengler, U. (2018). Direct antiviral agents (DAAs)-A new age in the treatment of hepatitis
C virus infection. Pharmacol. Ther. 183, 118–126. doi: 10.1016/j.pharmthera.2017.10.009
Capileno, Y. A., Van den Bergh, R., Donchunk, D., Hinderaker, S. G., Hamid, S., Auat,
R., et al. (2017). Management of chronic Hepatitis C at a primary health clinic in the highburden context of Karachi, Pakistan. PloS One 12 (4), e0175562.
European Association for the Study of the Liver. EASL recommendations on treatment of
hepatitis C 2016. J Hepatol. 2017;66:153–94.
Mushtaq, L., Singh, S. J., Yatoo, G. N., Gulzar, G. M., & Gulzar, D. (2018). 26.
Comparison of daclatasvir/sofosbuvir with sofosbuvir/ribavirin in the treatment of chronic hepatitis-C genotype-3 in Kashmiri population. Journal of Clinical and Experimental
Hepatology, 8, S26.
Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification
of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3
infection: A systematic review and network meta-analysis. Clin Gastroenterol Hepatol.
;15:349–59.
Osinusi A, Meissner EG, Lee YJ, et al. Efficacy of sofosbuvir and ribavirin for treatment
of hepatitis C genotype-1 in an inner city population: virus and host factors that predict
relapse: a randomized controlled trial. JAMA. 2013;310:804–11.
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2
and 3. N Engl J Med. 2014;370:1993–2001.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
